COU-AA-301 is a 2:1 randomized , double-blind , placebo-controlled study comparing abiraterone ( 1000mg q.d. ) plus low-dose prednisone ( 5mg b.i.d. ) with placebo plus prednisone in mCRPC patients post docetaxel .